Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics


Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: target; # of requested predictions: 20; Secondary interactions: no
Input target 1: P16442
No. Gene UniProt ID Protein Name Pathway PDB
1 ABO P16442 Histo-blood group ABO system transferase hsa00601; hsa01100

13 known interactions (drugs) of input target (ABO): Histo-blood group ABO system transferase
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter
1 Experimental SmallMoleculeDrug DB04678 H TYPE II TRISACCHARIDE Thumb
2 Experimental SmallMoleculeDrug DB07341 octyl 3-amino-3-deoxy-2-O-(2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)-beta-D-galactopyranoside Thumb
3 Experimental SmallMoleculeDrug DB02196 Uridine-Diphosphate-N-Acetylgalactosamine Thumb
4 Experimental SmallMoleculeDrug DB04141 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol Thumb
5 Experimental SmallMoleculeDrug DB03501 Galactose-uridine-5'-diphosphate Thumb
6 Experimental SmallMoleculeDrug DB07378 4-AMINO-2-OCTYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL Thumb
7 Experimental SmallMoleculeDrug DB04680 GALACTOSE GREASE Thumb
8 Experimental SmallMoleculeDrug DB04681 BETA-METHYLLACTOSIDE Thumb
9 Experimental SmallMoleculeDrug DB04679 H TYPE I TRISACCHARIDE Thumb
10 Experimental SmallMoleculeDrug DB03772 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,5-Diol Thumb
11 Experimental SmallMoleculeDrug DB07633 octyl 3-deoxy-2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-xylo-hexopyranoside Thumb
12 Experimental SmallMoleculeDrug DB07357 4-AMINO-2-HEXYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL Thumb
13 Experimental SmallMoleculeDrug DB03435 Uridine-5'-Diphosphate Thumb

20 predicted interactions (drugs) of input target (ABO): Histo-blood group ABO system transferase
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter
Image Confidence score
1 Approved;
SmallMoleculeDrug DB00126 Vitamin C Thumb 39.7%
2 Experimental SmallMoleculeDrug DB03397 Uridine-Diphosphate-N-Acetylglucosamine Thumb 36.5%
3 Experimental SmallMoleculeDrug DB01861 Uridine diphosphate glucose Thumb 33.3%
4 Approved SmallMoleculeDrug DB01250 Olsalazine Thumb 26.2%
5 Approved;
Vet approved
SmallMoleculeDrug DB08818 Hyaluronic acid Thumb 24.1%
6 Approved;
SmallMoleculeDrug DB01103 Quinacrine Thumb 23.9%
7 Approved;
SmallMoleculeDrug DB00156 L-Threonine Thumb 23.7%
8 Experimental SmallMoleculeDrug DB07763 (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE Thumb 23.6%
9 Approved;
SmallMoleculeDrug DB11638 Artenimol Thumb 23.3%
10 Approved;
SmallMoleculeDrug DB00133 Serine Thumb 23.3%
11 Approved;
SmallMoleculeDrug DB09130 Copper Thumb 23.0%
12 Experimental SmallMoleculeDrug DB03095 Tetramethylammonium Ion Thumb 22.1%
13 Approved;
SmallMoleculeDrug DB00149 L-Leucine Thumb 22.0%
14 Approved;
SmallMoleculeDrug DB09092 Xanthinol Thumb 21.9%
15 Approved;
SmallMoleculeDrug DB03017 Lauric Acid Thumb 20.8%
16 Experimental SmallMoleculeDrug DB01782 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Thumb 20.6%
17 Nutraceutical SmallMoleculeDrug DB00116 Tetrahydrofolic acid Thumb 20.4%
18 Experimental SmallMoleculeDrug DB07778 FAMOXADONE Thumb 20.2%
19 Experimental SmallMoleculeDrug DB03467 Naringenin Thumb 20.2%
20 Approved;
Vet approved;
SmallMoleculeDrug DB01108 Trilostane Thumb 19.6%


Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.


The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.